Sanofi-Aventis' Lovenox is safer than standard of care, study says

By Elaine Rigoli

Tampa, Fla., Sept. 8 - The New England Journal of Medicine published results from Sanofi-Aventis SA's Steeple trial, which showed that a single intravenous bolus of Lovenox (enoxaparin sodium injection) of 0.5 mg/kg is associated with significantly less bleeding than the current standard, unfractionated heparin, in patients undergoing elective percutaneous coronary intervention or coronary angioplasty.

The data also showed that both studied doses of the drug were associated with more predictable anticoagulation levels than unfractionated heparin with similar efficacy, according to a company news release.

Steeple (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention: An International Randomized Evaluation) was an international, prospective, randomized, open-label, parallel group trial evaluating the safety and efficacy of a single intravenous bolus of enoxaparin 0.5 mg/kg and 0.75 mg/kg versus Activated Clotting Time-adjusted intravenous unfractionated heparin in patients undergoing non-emergency percutaneous coronary intervention.

Percutaneous coronary intervention is a non-surgical treatment procedure that unblocks coronary arteries that have narrowed due to atherosclerosis or atherothrombosis. The Paris-based pharmaceutical company said the procedure is performed in non-emergency cases of coronary arterial disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.